TRENTON, N.J. (AP) — The U.S. Food and Drug Administration has approved the first generic copies of a popular, pricey pill for nerve pain.
The agency on Monday said it approved nine generic versions of Pfizer Inc.'s Lyrica. It is also used for seizures and fibromyalgia, a condition that causes chronic, widespread pain.
Lyrica, approved in 2004, is Pfizer's second bestseller, with sales last year of $4.6 billion. The heavily advertised drug costs about $460 to $720 per month without insurance, depending on the pharmacy. Prices can vary widely.
Prices for generic versions range from about $140 to $370 per month, according to the drug price comparison site GoodRx .
Common side effects include dizziness, blurred vision and sleepiness. Serious side effects include allergic reactions and life-threatening breathing problems.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
